Clinical trial NCT05720494: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JZP441 in Healthy Participants
Official title: Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of JZP441 in Healthy Adult Participants: A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Participants
Keywords: Healthy Participants
JZP441
Lead sponsor: Jazz Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2023-02-09
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Treatments for narcolepsy and hypersomnolence disorders should have good oral bioavailability and brain penetration properties. JZP441 has demonstrated wake-promoting efficacy and anticataplectic activity in nonclinical studies and may represent a novel approach for these patients.

Detailed description: This Phase 1, double-blind, randomized, placebo-controlled, parallel group study is designed to characterize the safety, tolerability, and PK of multiple ascending doses of JZP441 for up to 4 weeks in healthy adult participants.

Eligibility criteria: Inclusion Criteria:

* Is 18 to 50 years of age inclusive, at the time of signing the informed consent
* Are overtly healthy as determined by medical evaluation, including medical history, physical exam, laboratory tests, and cardiac/blood pressure monitoring.

Exclusion Criteria:

* History or presence of gastrointestinal (including prior bariatric bypass surgery), hepatic or renal disease, or any other condition that, in the investigator opinion, may interfere with absorption, distribution, metabolism, or excretion of drugs
* Presence of renal impairment or calculated eGFR \< 80 mL/min/1.73 m\^2.
* Triplicate 12-lead ECG demonstrating a mean QTcF \> 450 msec for males and \> 470 msec for females or any other clinically significant ECG abnormality per investigator assessment prior to dose of study intervention
* Presence or history of significant cardiovascular disease including (but not limited to): myocardial infarction, uncontrolled hypertension, systolic BP ≥ 140 mmHg or diastolic BP ≥ 90 mmHg (at Screening or baseline consistent with protocol specifications), angina pectoris, clinically significant arrhythmias, clinically significant valvular heart disease, history of any revascularization procedures or second or third degree heart block with/without a pacemaker, heart failure, or family history of Torsades de Pointes
* Current diagnosis of or receiving treatment for depression; past (within 5 years) clinically significant major depressive episode; history of suicide attempt, current suicidal risk as determined from history, or presence of active suicidal ideation as indicated by a positive response to item 4 or item 5 on the C-SSRS (within the past 6 months)
* History or presence of bipolar disorder, bipolar related disorders, schizophrenia, schizophrenia spectrum disorders, or clinically significant psychiatric disorders, including other psychotic disorders
* History (within past 2 years at Screening) or presence of substance use disorder (including alcohol) or seeking treatment for alcohol or substance abuse related disorder
* History of seizure disorder or a physical condition that would increase seizure risk
* History of head trauma or concussions that are deemed clinically significant by the investigator
* Have used tobacco products or products for smoking cessation within 90 days before screening, including nicotine-containing products, or history of significant use of tobacco (\> 10 cigarettes or equivalent per day) within 1 year before Screening, or unwilling to refrain from nicotine-containing products for the duration of the study
* Participants who are taking a concomitant medication or supplement that lowers seizure threshold (eg, kratom)
* Participants who have recently (\< 2 weeks) discontinued a drug or supplement for which discontinuation would lower seizure threshold (eg, benzodiazepine medication)
* Participation in a previous JZP441 clinical study
* Positive alcohol test or urine drug screen (including cannabinoids and cotinine) at Screening or at any point throughout the duration of the study
* Presence at Screening of HIV antibody, Hepatitis B surface antigen, Hepatitis C antibody, or a clinical history of these infections
* History of clinically significant acute or chronic insomnia within the last 5 years

Primary outcomes:
measure: Number of Participants With Treatment-emergent Adverse Events
timeFrame: Day 1 up until 38 days after last dose of study drug, up to approximately 2 months
measure: Pharmacokinetic Parameter Maximum Plasma Concentration (Cmax) Levels of JZP441
timeFrame: Pre-dose and multiple post-dose timepoints, up to Day 28
measure: Pharmacokinetic Parameter Time to Maximum Plasma Concentration (Tmax) of JZP441
timeFrame: Pre-dose and multiple post-dose timepoints, up to Day 28
measure: Pharmacokinetic Parameter Terminal Elimination Half-life (T1/2) of JZP441
timeFrame: Pre-dose and multiple post-dose timepoints, up to Day 28
measure: Pharmacokinetic Parameter Area Under the Concentration-Time Curve (AUC) of JZP441
timeFrame: Pre-dose and multiple post-dose timepoints, up to Day 28
measure: Pharmacokinetic Parameter Apparent Oral Clearance (CL/F) of JZP441
timeFrame: Pre-dose and multiple post-dose timepoints, up to Day 28
measure: Pharmacokinetic Parameter Apparent Volume of Distribution (Vz/F) of JZP441
timeFrame: Pre-dose and multiple post-dose timepoints, up to Day 28
measure: Pharmacokinetic Parameter Accumulation Ratio of JZP441
timeFrame: Pre-dose and multiple post-dose timepoints, up to Day 28
measure: Dose Proportionality of JZP441 for Maximum Concentration (Cmax)
timeFrame: Pre-dose and multiple post-dose timepoints, up to Day 28
measure: Dose Proportionality of JZP441 for Area Under the Concentration-Time Curve (AUC)
timeFrame: Pre-dose and multiple post-dose timepoints, up to Day 28
Secondary outcomes:
Other outcomes:
Locations:
city: Salt Lake City
country: United States
facility: Clinical Site 1
state: Utah
Study officials:
References: